The Effects of Dual-strain Probiotics on the Weight Gain in Premature Neonates

We published an RCT in the Journal of Global Pediatrics in 2023 showing that dual-strain probiotics significantly improved weight gain in preterm neonates. Recently, two meta-analyses have supported our findings. The abstract is shared here to highlight this important issue.

Published in Biomedical Research

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Explore the Research

MDPI
MDPI MDPI

Unveiling the Growth Impact of Probiotics in Neonates: To BEgin or Not to BEgin?

Background/Objectives: This study aimed to evaluate the supportive role of probiotic supplementation in neonatal weight gain through a meta-analysis of published studies. Given the conflicting results in the literature, the objective was to determine the overall effect size and assess the influence of regional and intervention-specific factors. Methods: A total of 20 studies published between 2011 and 2022 were included, comprising a combined sample size of 3929 neonates. A random-effects model was used to calculate the pooled standardized mean difference (SMD) in neonatal weight gain attributable to probiotic supplementation. Heterogeneity among studies was assessed using the I2 statistic. Subgroup analyses were conducted based on geographic region, probiotic strain, dosage, and treatment duration. Results: The pooled analysis demonstrated a modest but non-significant positive effect on neonatal weight gain (SMD: 0.27; 95% CI: −0.06 to 0.61), with substantial heterogeneity across studies (I2 = 91%). Subgroup analyses indicated that regional variations, particularly in studies conducted in China, were associated with a more favorable effect. However, not all studies reported a benefit; some found no difference or even negative effects, particularly in discharge weight outcomes. Conclusions: Probiotic supplementation shows potential for improving neonatal weight gain, but findings remain inconsistent and heterogeneous. Strain selection, dosage, and treatment duration appear to be critical variables influencing outcomes. Future large-scale, multicenter randomized controlled trials are necessary to develop standardized, evidence-based guidelines for probiotic use in neonatal care.

ABSTRACT

Background: Prematurity is prevalent worldwide and accounts for the leading cause of neonatal death. Preterm neonates face numerous challenges, including slow weight gain, prolonged hospital stays, and high mortality. Dual-strain probiotics containing Bifidobacterium bifidum and Clostridium butyricum can manage such complications of prematurity. Therefore, the present study was conducted to evaluate the effectiveness of dual-strain probiotics consisting of Bifidobacterium bifidum and Clostridium butyricum on the weight gain of preterm neonates in Kabul City. 
Methods: This randomized clinical trial was conducted at the Neonatal Units of Malalai Maternity and Maiwand Teaching Hospitals in Kabul City. Finally, 84 preterm neonates were assessed for the effects of dual-strain probiotics. The clinical parameters were daily weight gain and the risks of feeding intolerance and neonatal mortality. Statistical analysis was performed by SPSS 26. 
Results: Forty-two premature neonates in the probiotics group and another forty-two preterm babies in the control group were investigated. In the probiotic group, 250 mg or 25 × 10
8 CFU of dual-strain probiotics dissolved in 1–3 ml milk were given twice daily for three weeks. At the time of intervention, the preterm neonates in the probiotics versus control group had amean age of (7 ± 3.3 vs 6.8 ± 3.3 days; P = 0.69), weight of (1497.5 ± 272 vs 1483.3 ± 271 g; P = 0.8) andgestational age of (33.6 ± 2 vs 33 ± 2.4 weeks; p = 0.31). Gender distribution in the probiotics group was (boys 54.8%, girls 45.2%) and in the control group it was (boys 50%, girl 50%). The premature newborns in the probiotics versus control group had a higher mean daily weight gain (15.5 ± 9.4 vs 10 ± 7.9 g; P = 0.001), lower mean age to reach full enteral feeds (8.74 ± 3.08 vs10.81 ±3.43 days, P = 0.005) and lower mean hospital stays (10.02 ± 4.68 vs 12.81 ± 4.86 days, P = 0.009) . The risk ratios of feeding intolerance and mortality during the hospital stays were (RR=0.59, P = 0.71) and (RR=0.67, P = 0.5) in probiotics and non-probiotics groups respectively. 
Conclusion: Dual-strain probiotics consisting of Bifidobacterium bifidum and Clostridiumbutyricum significantly improved the daily weight gain and decreased the time tofull enteral feeding and admission days for premature neonates.   

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in